Gemcitabine in the treatment of recurrent epitherlial ovarian cancer.


5141 Background: Five years survival of patients with advanced epithelial ovarian cancer (EOC) is 25-40% and once the disease recurs, treatment is mainly palliative. We would like to give that treatment with the longest time to progression (TTP) together with the best quality of life. Our objectives in this study were to evaluate the safety and to determine… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics